Table 3.
Effect of ZnO NPs on liver antioxidant enzymes and LP
| Group I (control) | Group II (diabetic control) | Group III (positive control – glibenclamide) | Group IV (ZnO NPs 5 mg/kg b.wt) | Group V (ZnO NPs 10 mg/kg b.wt) | |
|---|---|---|---|---|---|
| CAT (μmole of H2 O2 consumed/min mg protein) | 471.45 ± 38.35 | 276.81 ± 18.09a* | 741.93 ± 60.38a*b** | 448.84 ± 47.84 | 691.17 ± 56.79 b** |
| SOD (nmol of enzyme/g tissue) | 189.86 ± 4.11 | 146.27 ± 4.93 a** | 150.00 ± 7.23 a* | 193.38 ± 7.12 b** | 173.20 ± 6.34 b* |
| GPx (U/mg protein) | 19.37 ± 1.61 | 13.59 ± 0.70 a* | 23.22 ± 2.63 b* | 15.84 ± 0.83 | 18.28 ± 1.70 |
| LPx (nmol/mg protein) | 0.09 ± 0.00 | 0.18 ± 0.01 a** | 0.07 ± 0.02 b** | 0.11 ± 0.02 b** | 0.09 ± 0.01 b** |
Values are mean±SEM, n = 6, *p < 0.05, **p < 0.01. Statistical analysis – ANOVA followed by Tukey's comparison test. a: comparison of group I with other groups and b: comparison of group II with other groups.